RE: Lack of news2 Oct 2024 13:41
Dr Michael Owen has had a varied career in biomedical research, and in the pharmaceutical and biotechnology industries. He was the co-founder and first CSO of Kymab Ltd, a biopharmaceutical company based in Cambridge, UK, which was acquired by Sanofi for up to £1.45 billion in 2021. Prior to Kymab, he worked for GSK where he was SVP and head of research for biopharmaceuticals R&D. His academic career was spent at the Imperial Cancer Research Fund (now CR-UK). In addition to the Board positions listed below, he chairs the SAB of Avacta plc, is a member of the R&D Investment Advisory Committee of Apollo Therapeutics and advises a number of Venture Capital LPs. Mike received an MA from Oxford University and a PhD from Cambridge University, and is an elected member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.
Michael is also a non-executive director of ReNeuron plc, Zealand Pharma A/S, and the chairman of Ossianix Inc.